The 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) was held from Wednesday, October 11, to Saturday, October 14, in Berlin, Germany. The annual EADV congress is one of the most significant global dermatology gatherings, featuring over 600 speakers from 50+ countries.
The following report covers thirteen of the latest and most inspiring updates on psoriasis, including the International Psoriasis Council’s (IPC) Symposium: Innovations in the Pathogenesis and Treatment of Psoriasis with presentations on Epigenetics, Disease Relapse and Progression, and Treatment Innovation, alongside late-breaking sessions focusing on psoriasis. Download the full EADV Congress Report or read on for highlights.
IPC SYMPOSIUM – INNOVATIONS IN THE PATHOGENESIS AND TREATMENT OF PSORIASIS
- Dr. Johann Gudjonsson, IPC Board Member, presented New Insights in the Pathogenesis of Psoriasis, revealing that psoriasis is a complex immunogenetic disease with relevant differences in immunogenetic background between psoriasis phenotypes. Additional insights into the immunogenetic background and crosstalks between cells could optimize treatment.
- Dr. Hervé Bachelez, IPC President, shared Updates on the Pathogenesis and Treatment of Generalized Pustular Psoriasis (GPP), unveiling that the single gene models for pustular disease led to targeted therapies like spesolimab. However, the disease’s genetic heterogeneity and its mechanistic consequences still pave the way for a precision medicine approach.
- Dr. Irène Gallais Sèrèzal, IPC Councilor, presented New Understandings of Disease Relapse and Progression, emphasizing that resolved skin relapses differ from nonlesional skin. Understanding spontaneous psoriasis resolution and insights into how to change disease memory in the skin is essential, and the fatty acid composition of the skin could be a potential marker for time to psoriasis relapse.
- Dr. Axel Svedbom shared insights on The Natural Course of Psoriasis: Insights into Clinical and Genetic Markers, indicating its importance in understanding severe disease development factors, including onset severity, age of onset, sex, weight, smoking, and genetic factors.
- Professor Richard Warren, IPC Councilor, presented New Paradigms in Oral Treatments for Psoriasis, providing an update on new oral compounds that block cytokines (IL23, IL17) with promising early-phase results.
- Dr. Ronald Vender, IPC Councilor, discussed TYK2 Inhibitors for the Treatment of Psoriasis, explaining that TYK2 inhibitors are a specific class of JAK inhibitors that are effective for treating psoriasis but have a different safety profile than the classical JAK inhibitors used for atopic dermatitis and rheumatoid arthritis. The TYK2 inhibitors under development show promising results, except for a topical TYK2 inhibitor that did not provide additional value.
- Dr. Curdin Conrad, IPC Councilor, discussed Long-term Remissions Through Disease Modification: Are We There Yet?, addressing psoriasis chronicity, recurrence, and the role of T-cell and inflammatory memory. Evidence on early intervention with biologics and the effect on disease memory was explored.
- Professor Wolf-Henning Boehncke, IPC Councilor, presented Early Detection and Prevention of Psoriatic Arthritis, showcasing the need for better screening for PsA based on the newest developments. Dermatologists often initiate systemic therapy/DMARDs later than rheumatologists after a PsA diagnosis.
LATE BREAKING SESSIONS
- Dr. Zenas Yiu discussed the Drug Survival of Interleukin-23 p19 Inhibitors Compared to Other Biologics for Psoriasis: A Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), emphasizing the need for improved statistical methods and showed that IL23-p19 inhibitors consistently exhibited the best drug survival rates.
- Dr. Alexander Egeberg, IPC Councilor, presented The Effects of Oral Roflumilast Therapy on Body Weight and Cardiometabolic Parameters in Patients with Psoriasis – Findings from the PSORRO Study, demonstrating its effectiveness and safety while contributing to significant weight loss in many patients.
- Professor Lars Iversen and Curdin Conrad, IPC Councilor, debated Can We Change the Disease Course of Psoriasis?, discussing levels of evidence and recent studies on disease memory and the effects of early intervention with biologics.
FREE COMMUNICATIONS V
- Dr. Kim A. Papp spoke about how Deucravacitinib Significantly Improves Symptoms and Signs of Psoriasis in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 POETYK PSO-1 and PO-ETYK PSO-2 Trials, demonstrating how TYK2 inhibitor deucravacitinib can significantly improve patient-reported symptoms and signs of psoriasis.
- Dr. Joseph Merola, IPC Councilor, presented data on Deucravacitinib, an Oral Selective Tyrosine Kinase 2 Inhibitor, vs. Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Subgroup Analyses of Phase 3 Studies Examining Psoriasis Symptom and Sign Diary and Dermatology Life Quality Index Scores, highlighting the effects on patient-reported outcomes and DLQI scores in multiple subgroups (e.g., age groups, males vs. females, weight groups, etc.). In most subgroup analyses, the results favored deucravacitinib over apremilast and placebo.
For those seeking a more comprehensive understanding of the sessions, we encourage you to download the full EADV Congress Report.